CN103408530B - Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof - Google Patents
Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof Download PDFInfo
- Publication number
- CN103408530B CN103408530B CN201310374912.0A CN201310374912A CN103408530B CN 103408530 B CN103408530 B CN 103408530B CN 201310374912 A CN201310374912 A CN 201310374912A CN 103408530 B CN103408530 B CN 103408530B
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- coumarin
- coumarin skeleton
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- -1 Coumarin skeleton polycyclic compound Chemical class 0.000 title claims abstract description 9
- 230000004071 biological effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 40
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 21
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 20
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 claims description 20
- 229910052710 silicon Inorganic materials 0.000 claims description 20
- 239000010703 silicon Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 229960000956 coumarin Drugs 0.000 claims description 9
- 235000001671 coumarin Nutrition 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 7
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 239000012454 non-polar solvent Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 238000005698 Diels-Alder reaction Methods 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 14
- 125000003118 aryl group Chemical group 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 6
- 125000004185 ester group Chemical group 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 150000002466 imines Chemical class 0.000 abstract description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- 125000004434 sulfur atom Chemical group 0.000 abstract description 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000011084 recovery Methods 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000004440 column chromatography Methods 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 230000006837 decompression Effects 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 0 *C(CC1c(c(*)c(*)c(*)c2*)c2O2)=C(*)C3[C@@]11C2=*=C1CCC3 Chemical compound *C(CC1c(c(*)c(*)c(*)c2*)c2O2)=C(*)C3[C@@]11C2=*=C1CCC3 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 2
- 102100020870 La-related protein 6 Human genes 0.000 description 2
- 108050008265 La-related protein 6 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006362 organocatalysis Methods 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention relates to a coumarin skeleton polycyclic compound with biological activity as well as a preparation method and use thereof. The general formula structure of the compound is shown in the specification, wherein, * represents a chiral carbon atom, R1 and R2 are respectively any one of C1-C16 alkyl, heteroaromatic ring or substituted aromatic ring; R3 is any one of H or C1-C16 alkyl or aryl; R4-R7 are respectively any one of H, F, Cl, Br, ester group, cyano, sulfuryl, nitro, heteroaromatic ring, C1-C16 oxyl, C1-C16 alkyl or substituted aromatic ring, and X is any one of O, X N, S atoms or imine, ketoxime and aromatic hydrazone. The compound has excellent region and stereoselectivity and a plurality of special physiological activities and tumor cell proliferation inhibition activities, and can be used for researching and developing antitumor drugs.
Description
Technical field
The present invention relates to a kind of medicinal chemistry arts, particularly one has bioactive coumarin skeleton polynuclear compound and preparation method and purposes.
Background technology
Coumarin skeleton, the polynuclear compound especially based on this type of skeleton structure is extensively present in natural product and pharmaceutical intermediate, this compounds pharmaceutically vital role caused the interest of increasing chemist.Modify the substituting group of this compounds, synthesis and the bioactive research thereof of analog become study hotspot.[a)S.M.Sethna,N.M.Shah,Chem.Rev.1945,36,1;b)S.V.Ukhov,M.E.Kon’shin,T.F.Odegova,Pharm.Chem.J.2001,35,364;c)B.Musicki,A.M.Periers,P.Laurin,D.Ferroud,Y.Benedetti,S.Lachaud,F.Chatreaux,J.L.Haesslein,A.Iltis,C.Pierre,J.Khider,N.Tessot,M.Airault,J.Demassey,C.Dupuis-Hamelin,P.Lassaigne,A.Bonnefoy,P.Vicat,M.Klich,Bioorg.Med.Chem.Lett.2000,10,1695;d)S.Chimichi,M.Boccalini,B.Cosimelli,G.Viola,D.Vedaldi,F.Dall’Acqua,Tetrahedron Lett.2002,43,7473;e)N.S.Reddy,K.Gumireddy,M.R.Mallireddigari,S.C.Cosenza,P.Venkatapuram,S.C.Bell,E.P.Reddy,M.V.R.Reddy,Bioorg.Med.Chem.2005,13,3141;f)F.Uchiumi,T.Hatano,H.Ito,T.Yoshida,S.Tanuma,Antiviral Res.2003,58,89;g)R.Fre′de′rick,S.Robert,C.Charlier,J.de Ruyck,J.Wouters,B.Pirotte,B.Masereel,L.Pochet,J.Med.Chem.2005,48,7592;h)S.Robert,C.Bertolla,B.Masereel,J.-M.Dogne,L.Pochet,J.Med.Chem.2008,51,3077;i)I.E.Bylov,M.V.Vasylyev,Y.V.Bilokin,Eur.J.Med.Chem.1999,34,997.]。But prepared the correlative study of chirality tonka bean camphor polynuclear compound by asymmetry catalysis method, the organocatalysis mode especially by environmental protection does not also have relevant report at present.Therefore, development is a kind of easy and simple to handle, environmental friendliness, and the synthesis of high enantioselectivity has coumarin skeleton diversity and the method with the chipal compounds storehouse of potential medical active has great significance.
Summary of the invention
The object of this invention is to provide a kind of coumarin skeleton polynuclear compound with multiple potential source biomolecule activity, described compound has outstanding regioselectivity and stereoselectivity, and it is active to have multiple special physiological, find that this compounds has inhibition tumor cell proliferation activity through cytotoxicity experiment, can be used as the research and development of lead compound for new type antineoplastic medicine.
Of the present invention have bioactive coumarin skeleton polynuclear compound, has following formula:
Wherein, * is chiral carbon atom, R
1, R
2be independently of one another the alkyl of C1-C16, fragrant heterocycle or
any one of aromatic ring replaced; R
3for any one in the alkyl of H or C1-C16 or aryl; R
4, R
5, R
6, R
7be independently of one another H, F, Cl, Br, ester group, cyano group, sulfuryl, nitro, fragrant heterocycle, the-oxyl of C1-C16, the alkyl of C1-C16 or
any one of aromatic ring replaced, X is any one in O, N, S atom or imines, ketoxime, aryl hydrazone.
Work as R
1, R
2for
time, R
1, R
2, R
3, R
4or R
5be independently of one another H, F, Cl, Br, ester group, cyano group, sulfuryl, nitro, the-oxyl of C1-C16, the alkyl of C1-C16 any one.
Work as R
4, R
5, R
6, R
7for
time, wherein R
1, R
2, R
3, R
4or R
5be any one in the alkyl of the-oxyl of H, F, Cl, Br, C1-C16, C1-C16 independently of one another.
Second object of the present invention is to provide a kind of preparation method with the active coumarin skeleton polynuclear compound of multiple potential source biomolecule, and the method catalyzer is easy to get, and catalytic activity is high, and reaction conditions is gentle, simple to operate.
There is the preparation method of bioactive coumarin skeleton polynuclear compound, have following steps:
One kettle way, under acid additives, in organic solvent, under the condition of-20 DEG C ~ 50 DEG C, 3-ethanoyl coumarin compound [Xu Cuilian, Chen Gang, Xia Baigen, Su Hui, Jiang Zhihong, Deng Shuguang, Yang Nan, chemistry circular .2009, 9, 815-819.] and two olefine aldehydr [Z.-J.Jia, Q.Zhou, Q.-Q.Zhou, P.-Q.Chen, Y.-C.Chen, Angew.Chem.Int.Ed.2011, 50, 8638] be raw material, chiral alpha, α-diaryl Prolinol silicon ether [J.-L.Li, S.-L.Zhou, P.-Q.Chen, L.Dong, T.-Y.Liu, Y.-C.Chen, Chem.Sci.2012, 3, 1879.] Diels-Alder reaction is carried out as catalyzer, 20 ~ 120 hours reaction times, DBU is added at 25 DEG C, series connection Diels-Alder/Aldol reacts 2 hours, reaction expression is as follows:
at 0 DEG C, MsCl, TEA dehydration reaction obtains target product in 15 minutes.
The good technical scheme of the present invention is; one kettle way, under acid additives, in organic solvent at 0 DEG C; with 3-ethanoyl coumarin compound and two olefine aldehydrs for raw material; chiral alpha, the Diels-Alder reaction that α-diaryl Prolinol silicon ether carries out as catalyzer, 20 ~ 120 hours reaction times is not etc.; after TLC monitoring reacts completely; add DBU, at 25 DEG C, carry out Aldol react 2 hours, finally add MsCl, TEA dehydration reaction at 0 DEG C and obtain target product in 15 minutes.
The structural formula of the coumarin compound of 3-ethanoyl described in above-mentioned method is:
wherein: R
4, R
5, R
6, R
7be selected from arbitrarily H, F, Cl, Br, ester group, cyano group, sulfuryl, nitro, fragrant heterocycle, the-oxyl of C1-C16, the alkyl of C1-C16 or
the aromatic ring replaced, wherein R
1, R
2, R
3, R
4or R
5be selected from arbitrarily the-oxyl of H, F, Cl, Br, C1-C16, the alkyl of C1-C16;
The structural formula of two olefine aldehydrs described in above-mentioned method is:
wherein: R
1, R
2be selected from arbitrarily fragrant heterocycle, C1-C16 alkyl or
the aromatic ring replaced, wherein R
1, R
2, R
3, R
4or R
5be selected from arbitrarily the-oxyl of H, F, Cl, Br, C1-C16, the alkyl of C1-C16, ester group, cyano group, sulfuryl, nitro, R
3be selected from arbitrarily alkyl or the aryl of H, C1-C16;
Chiral alpha described in above-mentioned method, the general structure of α-diaryl Prolinol silicon ether catalyst is (any optically pure structure not limit by diagram):
wherein: R
1, R
2be selected from H, CH arbitrarily
3, tBu, OCH
3, R
3be selected from TMS, TES, TBS arbitrarily, R
4be selected from H arbitrarily, OTBS.
Described in above-mentioned method, acid additives is selected from protonic acid arbitrarily; Described DBU is 1,8-diazabicylo [5.4.0] 11 carbon-7-alkene; Described MsCl is methane sulfonyl chloride; Described TEA is triethylamine.
3-ethanoyl coumarin compound described in above-mentioned method, two olefine aldehydrs, chiral alpha, the mol ratio of α-diaryl Prolinol silicon ether, acid additives, DBU, MsCl, TEA is 1:2:0.2:0.2:0.5:2:5.
Organic solvent described in above-mentioned method is polar solvent or non-polar solvent, and described polar solvent is toluene, methylene dichloride, chloroform, acetonitrile, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF), ethyl acetate; Non-polar solvent is benzene, sherwood oil.Water described in the present invention is distilled water.
The product obtained by the present invention is adopted to be separated through the method for column chromatography.Developping agent used and eluent are the mixed solvent of polar solvent and non-polar solvent, and good solvent is sherwood oil/acetone.
Alkyl of the present invention,-oxyl etc., unless otherwise indicated, be all recommended as the group that carbon number is 1-16, recommends carbon number to be the group of 1-10 further, especially recommends carbon number to be the group of 1-4.
Aryl of the present invention, unless otherwise indicated, all refers to phenyl or naphthyl, is recommended as phenyl, described heterocycle be C5-C10 containing N, O, S heterocyclic radical.
Coumarin skeleton polynuclear compound of the present invention can be used for preparing Hepatoma therapy medicine, treatment kidney medicine, treatment cervical cancer medicine, treatment prostate cancer medicine, treatment lymphoid tumor medicament etc.
The present invention is with the α of chirality; α-diaryl Prolinol silicon ether is as catalyzer; be raw material by 3-ethanoyl coumarin compound and two olefine aldehydrs, a kind of method with the coumarin skeleton polynuclear compound of multiple lateral reactivity of the synthesis of high-level efficiency, highly-solid selectively.The method catalyzer is easy to get, catalytic activity is high, reaction conditions is gentle, simple to operate, wide application range of substrates, product structure is various, Atom economy good (atom in raw molecule is all transformed into product, does not produce by product or refuse), has environment friendly, yield high (ranging up to 95% yield), cis-selectivity higher (P1 ~ P11 is all greater than 95% de), enantioselectivity high (P1-(3aR, 7aS, 13bR)-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 90%ee; P2-(3aR, 7aS, 13bR)-12-bromo-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 87%ee; P3-(3aR, 7aS, 13bR)-12-chloro-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 87%ee; P4-(4aS, 12cR, 15aR)-15-phenyl-1,12c, 13,15a-tetrahydro benzo [f] naphtho-[8a, 1-c] chromene-4,5-diketone: 87%ee; P5-(3aR, 7aS, 13bR)-10-methoxyl group-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 96%ee; P6-(3aR, 7aS, 13bR)-10-oxyethyl group-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 94%ee; P7-(3aR, 7aS, 13bR)-7,8-dioxy-3-phenyl-1,3a, 4,7,8,13b-hexahydro naphthalene also [8a, 1-c] chromene-12-acetic ester: 89%ee; P8-(3aR, 7aS, 13bR)-12-methoxyl group-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 93%ee; P9-(3aR, 7aS, 13bR)-12-phenyl-3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 92%ee; P10-(3aR, 7aS, 13bR)-10,12-dichloro--3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 73%ee; P11-(3aR, 7aS, 13bR)-3-ethyl-10-methoxyl group--3-phenyl-1,3a, 4,13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7,8-diketone: 86%ee).Test through cytotoxicity, find P1:(3aR, 7aS, 13bR)-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, P3:(3aR, 7aS, 13bR) the chloro-3-phenyl-1 of-12-, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, P5:(3aR, 7aS, 13bR)-10-methoxyl group-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, the compound on tumor cells such as 8-diketone have proliferation inhibition activity, the lead compound be expected to as new type antineoplastic medicine is studied further.
To contribute to understanding the present invention by following embodiment, but not limit content of the present invention.
Embodiment
Reagent:
3-ethanoyl coumarin compound [Xu Cuilian, Chen Gang, Xia Baigen, Su Hui, Jiang Zhihong, Deng Shuguang, Yang Nan, chemistry circular .2009,9,815-819.];
Two olefine aldehydrs [Z.-J.Jia, Q.Zhou, Q.-Q.Zhou, P.-Q.Chen, Y.-C.Chen, Angew.Chem.Int.Ed.2011,50,8638];
Chiral alpha, α-diaryl Prolinol silicon ether [J.-L.Li, S.-L.Zhou, P.-Q.Chen, L.Dong, T.-Y.Liu, Y.-C.Chen, Chem.Sci.2012,3,1879.]
Acid additives, DBU, MsCl, TEA are commercially available analytical pure.
Water described in the present invention is distilled water, and described organic solvent is commercially available analytically pure polar solvent or non-polar solvent, as: benzene, toluene, methylene dichloride, chloroform, acetonitrile, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF), sherwood oil, ethyl acetate etc.
Embodiment 1-11 all adopts one kettle way.
Embodiment 1
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 3-ethanoyl tonka bean camphor (0.1mmol, 18.8mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 42 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 1 by column chromatography for separation and is called (3aR, 7aS, 13bR)-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 87%, structural formula is as follows:
[α]
d 20=+152.4 (c=0.42in CHCl
3); 90%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=18.53min, t (minor)=11.84min];
1H NMR(400MHz,CDCl
3):δ=7.43-7.41(m,2H),7.37-7.33(m,2H),7.30-7.29(m,2H),7.18-7.16(m,1H),7.15-7.07(m,2H),6.90-6.86(m,1H),5.97(dd,J=10.0,1.6Hz,1H),5.78(t,J=4.0Hz,1H),3.95-3.94(m,1H),3.52(t,J=8.0Hz,1H),2.89-2.80(m,1H),2.71(dt,J=20.0,5.6Hz,1H),2.40-2.28(m,2H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.7,167.8,151.1,148.5,140.3,140.1,128.7,128.5,127.6,127.3,126.5,126.3,125.6,124.5,121.4,116.9,56.5,36.9,32.9,32.0,30.4ppm;
High resolution mass spectrum calculating value: C
23h
18o
3+ H343.1334, measured value: 343.1336.
Embodiment 2
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-bromo-3-ethanoyl tonka bean camphor (0.1mmol, 26.7mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 72 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 2 by column chromatography for separation and is called: (3aR, 7aS, 13bR) the bromo-3-phenyl-1 of-12-, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 76%, structural formula is as follows:
[α]
d 20=+162.9 (c=0.80in CHCl
3); 87%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=19.07min, t (minor)=17.72min];
1H NMR(400MHz,CDCl
3):δ=7.43-7.40(m,3H),7.37-7.34(m,2H),7.32-7.30(m,1H),7.27-7.26(m,1H),7.06-7.04(m,1H),6.93-6.88(m,1H),5.99-5.97(m,1H),5.77(t,J=4.0Hz,1H),3.98-3.95(m,1H),3.46(t,J=8.4Hz,1H),2.84(dq,J=20.0,4.0Hz,1H),2.72(dt,J=20.0,5.2Hz,1H),2.38-2.23(m,2H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.4,167.2,150.3,148.7,140.4,139.9,131.8,129.5,128.6,127.7,127.4,126.4,121.0,118.8,116.9,56.3,36.9,32.9,31.9,30.4ppm;
High resolution mass spectrum calculating value: C
23h
17brO
3+ H421.0439, measured value: 421.0437.
Embodiment 3
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-chloro-3-ethanoyl tonka bean camphor (0.1mmol, 22.2mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 12 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 3 by column chromatography for separation and is called: (3aR, 7aS, 13bR) the chloro-3-phenyl-1 of-12-, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 83%, structural formula is as follows:
[α]
d 20=+204.4 (c=0.78in CHCl
3); 87%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=20.04min, t (minor)=18.11min];
1H NMR(400MHz,CDCl
3):δ=7.43-7.41(m,2H),7.37-7.34(m,2H),7.32-7.25(m,2H),7.13-7.09(m,2H),6.92-6.88(m,1H),5.98-5.96(m,1H),5.77(t,J=3.6Hz,1H),3.96-3.95(m,1H),3.47(t,J=8.4Hz,1H),2.84(dq,J=20.0,4.0Hz,1H),2.71(dt,J=20.0,5.6Hz,1H),2.38-2.23(m,2H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.4,167.2,149.7,148.8,140.4,139.9,129.4,128.8,128.6,127.7,127.3,126.6,126.3,121.0,118.3,56.2,36.9,32.9,31.8,30.1ppm;
High resolution mass spectrum calculating value: C
23h
17clO
3+ H377.0944, measured value: 377.0948.
Embodiment 4
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 5, 6-naphthalene-3-ethanoyl tonka bean camphor (0.1mmol, 23.8mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 60 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 4 by column chromatography for separation and is called (4aS, 12cR, 15aR)-15-phenyl-1, 12c, 13, 15a-tetrahydro benzo [f] naphtho-[8a, 1-c] chromene-4, 5-diketone, recovery rate is 76%, structural formula is as follows:
[α]
d 20=+300.0 (c=0.62in CHCl
3); 87%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=34.08min, t (minor)=25.69min];
1H NMR(400MHz,CDCl
3):δ=7.91-7.85(m,2H),7.81(d,J=8.8Hz,1H),7.57-7.52(m,3H),7.47-7.43(m,1H),7.40-7.30(m,4H),6.93-6.89(m,1H),5.86-5.81(m,2H),4.18-4.11(m,2H),3.10(dq,J=20.0,4.0Hz,1H),2.80(dt,J=20.0,5.6Hz,1H),2.54-2.46(m,1H),2.32-2.24(m,1H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.6,167.8,148.9,148.5,140.8,140.1,130.9,129.2,129.0,128.6,127.7,127.1,127.0,126.4,124.9,121.8,120.7,119.0,117.6,56.1,37.4,32.1,30.9,28.9ppm;
High resolution mass spectrum calculating value: C
27h
20o
3+ H393.1491, measured value: 393.1492.
Embodiment 5
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 8-methoxyl group-3-ethanoyl tonka bean camphor (0.1mmol, 21.8mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 60 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 5 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-10-methoxyl group-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 95%, structural formula is as follows:
[α]
d 20=+277.5 (c=0.40in CHCl
3); 96%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=26.51min, t (minor)=32.86min];
1H NMR(400MHz,CDCl
3):δ=7.41-7.39(m,2H),7.35-7.31(m,2H),7.29-7.26(m,1H),7.05-7.00(m,1H),6.91-6.83(m,2H),6.73-6.70(m,1H),5.96(d,J=11.2Hz,1H),5.77(t,J=3.6Hz,1H),3.92(s,3H),3.92-3.89(m,1H),3.51(t,J=8.0Hz,1H),2.82(ddd,J=20.0,7.2,4.0Hz,1H),2.68(dt,J=20.0,5.2Hz,1H),2.38-2.28(m,2H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.6,167.1,148.3,147.5,140.2,128.5,127.5,127.4,126.6,126.4,124.6,121.4,118.1,112.0,56.2,36.8,33.1,30.3,25.3ppm;
High resolution mass spectrum calculating value: C
24h
20o
4+ Na395.1259, measured value: 395.1258.
Embodiment 6
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 8-oxyethyl group-3-ethanoyl tonka bean camphor (0.1mmol, 23.2mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 96 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 6 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-10-oxyethyl group-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate 88%, structural formula is as follows:
[α]
d 20=+195.2 (c=0.52in CHCl
3); 94%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=14.73min, t (minor)=16.96min];
1H NMR(400MHz,CDCl
3):δ=7.41-7.39(m,2H),7.36-7.32(m,2H),7.30-7.27(m,1H),7.02-6.98(m,1H),6.91-6.83(m,2H),6.72-6.69(m,1H),5.96(d,J=10.0Hz,1H),5.76(dd,J=4.0,3.6Hz,1H),4.21-4.01(m,2H),3.93-3.91(m,1H),3.50(dd,J=8.0,7.6Hz,1H),2.81(ddd,J=20.0,7.6,4.0Hz,1H),2.69(dt,J=20.0,5.6Hz,1H),2.38-2.29(m,2H),1.48(t,J=6.8Hz,3H)ppm;
13C NMR(100MHz,CDCl
3):δ=194.6,167.2,148.3,146.9,140.3,128.6,128.5,127.4,126.7,126.4,124.5,121.6,118.2,113.9,65.2,36.9,33.2,32.0,30.4,14.8ppm;
High resolution mass spectrum calculating value: C
25h
22o
4+ Na409.1416, measured value: 409.1412.
Embodiment 7
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-acetoxy-3-ethanoyl tonka bean camphor (0.1mmol, 24.6mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 72 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 7 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-7, 8-dioxy-3-phenyl-1, 3a, 4, 7, 8, 13b-hexahydro naphthalene also [8a, 1-c] chromene-12-acetic ester, recovery rate is 73%, structural formula is as follows:
[α]
d 20=+142.6 (c=0.74in CHCl
3); 89%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=60/40,1.0mL/min, λ=254nm, t (major)=25.61min, t (minor)=21.18min];
1H NMR(400MHz,CDCl
3):δ=7.41-7.39(m,2H),7.37-7.32(m,2H),7.31-7.28(m,1H),7.17-7.15(m,1H),7.04-7.01(m,1H),6.93-6.85(m,2H),5.97(d,J=10.0Hz,1H),5.77(t,J=3.6Hz,1H),3.92(bs,1H),3.50(dd,J=7.6,7.2Hz,1H),2.84(ddd,J=20.0,7.6,4.0Hz,1H),2.69(dt,J=20.0,5.2Hz,1H),2.38-2.29(m,2H),2.27(s,3H)pp；
13C NMR(100MHz,CDCl
3):δ=194.4,169.2,167.5,148.5,146.8,140.2,140.0,128.5,127.6,127.4,126.4,126.3,121.6,119.7,117.8,56.2,36.8,33.0,30.3,21.1ppm；
High resolution mass spectrum calculating value: C
25h
20o
5+ Na423.1208, measured value: 423.1209.
Embodiment 8
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-methoxyl group-3-ethanoyl tonka bean camphor (0.1mmol, 21.8mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 120 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 8 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-12-methoxyl group-3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 86%, structural formula is as follows:
[α]
d 20=+152.8 (c=0.68in CHCl
3); 93%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=60/40,1.0mL/min, λ=254nm, t (major)=22.40min, t (minor)=20.20min];
1H NMR(400MHz,CDCl
3):δ=7.43-7.40(m,2H),7.37-7.28(m,3H),7.10(d,J=9.2Hz,1H),6.90-6.85(m,1H),6.80(dd,J=8.8,2.8Hz,1H),6.67(d,J=2.8Hz,1H),5.97(d,J=10.0Hz,1H),5.78(dd,J=4.0,3.2Hz,1H),3.96-3.94(m,1H),3.78(s,3H),3.46(dd,J=7.6,7.2Hz,1H),2.83(ddd,J=20.0,7.2,4.0Hz,1H),2.70(dt,J=20.0,5.2Hz,1H),2.38-2.27(m,2H)ppm；
13C NMR(100MHz,CDCl
3):δ=194.8,167.9,156.1,148.4,144.9,140.2,128.5,127.6,127.5,126.5,126.4,121.4,117.7,112.8,112.5,55.5,36.9,33.2,31.8,30.4ppm；
High resolution mass spectrum calculating value: C
24h
20o
4+ Na395.1259, measured value: 395.1257.
Embodiment 9
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-phenyl-3-ethanoyl tonka bean camphor (0.1mmol, 26.4mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 120 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 9 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-3, 12-phenylbenzene-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 89%, structural formula is as follows:
[α]
d 20=+142.6 (c=0.74in CHCl
3); 92%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=60/40,1.0mL/min, λ=254nm, t (major)=31.13min, t (minor)=21.76min];
1H NMR(400MHz,CDCl
3):δ=7.54-7.50(m,4H),7.44-7.40(m,4H),7.37-7.22(m,5H),6.91-6.87(m,1H),5.98(d,J=10.0Hz,1H),5.79(t,J=3.6Hz,1H),3.99-3.98(m,1H),3.56(dd,J=8.0,7.6Hz,1H),2.89(ddd,J=19.6,7.6,4.0Hz,1H),2.72(dt,J=19.6,5.2Hz,1H),2.41-2.32(m,2H)ppm；
13C NMR(100MHz,CDCl
3):δ=194.7,167.7,150.6,148.5,140.4,140.1,140.0,137.7,128.8,128.5,127.6,127.5,127.3,126.9,126.4,125.9,125.3,121.3,117.3,56.6,37.1,33.2,32.2,30.5ppm；
High resolution mass spectrum calculating value: C
29h
22o
3+ K457.1206, measured value: 457.1207.
Embodiment 10
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6, 8-bis-chloro-3-ethanoyl tonka bean camphor (0.1mmol, 25.7mg), 4-phenyl-2, 4-sorbic aldehyde (0.2mmol, 34mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 20 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 10 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-10, 12-dichloro--3-phenyl-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 61%, structural formula is as follows:
[α]
d 20=+150.2 (c=0.44in CHCl
3); 73%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=10.52min, t (minor)=12.40min];
1H NMR(400MHz,CDCl
3):δ=7.43-7.40(m,2H),7.38-7.28(m,4H),7.02(d,J=2.0Hz,1H),6.94-6.89(m,1H),5.98(dd,J=10.4,1.6Hz,1H),5.77(t,J=4.0,3.6Hz,1H),3.98-3.95(m,1H),3.46(dd,J=8.8,8.4Hz,1H),2.84(dq,J=20.0,4.0Hz,1H),2.72(dt,J=20.0,5.6Hz,1H),2.37-2.23(m,2H)ppm；
13C NMR(100MHz,CDCl
3):δ=193.9,166.0,149.0,146.0,140.4,139.8,130.9,129.3,129.2,128.8,128.6,128.5,127.8,127.3,126.3,125.1,122.8,120.7,56.0,36.9,33.4,31.7,30.4ppm；
High resolution mass spectrum calculating value: C
23h
16o
3+ H411.0555, measured value: 411.0555.
Embodiment 11
In a clean 10ml reaction tubes, add chiral Prolinol silicon ether catalyst (0.02mmol successively, 14.8mg), 6-methoxyl group-3-ethanoyl tonka bean camphor (0.1mmol, 21.8mg), 4-ethyl-2, 4-sorbic aldehyde (0.2mmol, 25mg), L-Boc-2-phenylglycocoll (0.02mmol, 5mg) with chloroform (0.5mL), stirring reaction 72 hours at 0 DEG C, after TLC monitoring reaction terminates, add DBU(0.05mmol, 7.5 μ L), 25 DEG C are stirred 2 hours, add TEA(0.5mmol successively at 0 DEG C afterwards, 70 μ L) and MsCl(0.2mmol, 15.5 μ L) stir 15 minutes after, decompression and solvent recovery, residuum obtains product P 11 by column chromatography for separation and is called: (3aR, 7aS, 13bR)-3-ethyl-10-methoxyl group-1, 3a, 4, 13b-tetrahydrochysene naphtho-[8a, 1-c] chromene-7, 8-diketone, recovery rate is 65%, structural formula is as follows:
[α]
d 20=+38.3 (c=0.60in CHCl
3); 86%ee, chirality test condition HPLC analysis [Daicel chiralpak AD, n-hexane/i-PrOH=80/20,1.0mL/min, λ=254nm, t (major)=13.16min, t (minor)=8.47min];
1H NMR(400MHz,CDCl
3):δ=7.01(dd,J=8.4,7.6Hz,1H),6.92(ddd,J=10.0,5.2,3.2Hz,1H),6.88(d,J=8.4Hz,1H),6.68(d,J=7.6Hz,1H),5.95(d,J=10.0Hz,1H),5.33-5.32(m,1H),3.91(s,3H),3.45(t,J=8.0Hz,1H),3.27(dd,J=8.8,6.0Hz,1H),2.84(dt,J=20.0,5.2Hz,1H),2.67-2.60(m,1H),2.39-2.30(m,1H),2.18-2.08(m,3H),1.04(t,J=7.2Hz,3H)ppm；
13C NMR(100MHz,CDCl
3):δ=194.9,167.1,147.9,147.4,130.9,128.8,127.6,126.9,124.4,118.0,116.9,111.8,56.2,36.8,33.3,30.5,29.9,27.9,11.8ppm；
High resolution mass spectrum calculating value: C
20h
20o
4+ Na347.1259, measured value: 347.1259.
Embodiment 12
Cytotoxicity is tested: CCK-8 method measures the impact of compound on tumor cell proliferation
(1) cell strain: choose human foetus liver cell L02, hepatocellular carcinoma cells HepG2, Huh7, vascular endothelial cell EA.hy926, cervical cancer cell HeLa, renal epithelial cell HEK293, kidney cancer cell ACHN, lymphoma cell Jeko, Namalwa, prostate cancer cell DU145 totally 10 kinds of clones test.
(2) testing method (CCK-8 method): 2000, the cell in vegetative period of taking the logarithm is inoculated in 96 orifice plates, every hole 100ul, is divided into blank group and compound group.After cell normally cultivates 12h, in cell culture medium by 0,1.25,2.5,5,10,20,40 μm of ol/L totally 7 concentration gradients add compound, often group establishes 3 multiple holes.After cellar culture 48-72h, by centrifugal for every hole, abandon supernatant, respectively add the CCK8 of RPMI-1640 containing 10%FBS and 10 μ l, in 37 DEG C, hatch 1 hour in 5%CO2 incubator, microplate reader is determined at the absorption photometric value (A value) under 450nm wavelength, then calculates the growth-inhibiting situation of compound on intracellular, using half-inhibition concentration (IC50) as Testing index.
(3) measurement result: in table 1.Compound all has proliferation inhibition activity (LO2: human foetus liver cell, Huh7, HepG2: human liver cancer cell to 10 kinds of cells; EA.hy926: human vascular endothelial; HeLa: human cervical carcinoma cell; HEK293: HEKC; ACHN: human renal carcinoma cell; Jeko: people's lymphoma mantle cell cell; Namalwa: human B cell lymphoma cell; DU145: prostate cancer cell).
Table 1 compound half-inhibition concentration (μm ol/L)
Conclusion a: class of the inventive method synthesis has the novel coumarin framework compound of multichiral center, has outstanding regioselectivity and stereoselectivity.It is active that such chipal compounds has multiple special physiological, and yield is waited until very well (reaching as high as 95%yield) in can reaching, cis-selectivity higher (being greater than 95%de), enantioselectivity high (being up to 96%ee).Show that this compounds has inhibition tumor cell proliferation activity through cytotoxicity experiment, the research and development of new type antineoplastic medicine may be used for as lead compound.
Claims (11)
1. there is a bioactive coumarin skeleton polynuclear compound, it is characterized in that, there is following formula:
Wherein, * is chiral carbon atom, R
1for phenyl, R
2-R
3, R
5for H, R
4for H or Cl, R
6for H or methoxyl group, X is O.
2. the preparation method of compound according to claim 1, is characterized in that, has following steps:
Under one kettle way acid additives; in organic solvent; under the condition of-20 DEG C ~ 50 DEG C, 3-ethanoyl coumarin compound and two olefine aldehydrs are raw material, chiral alpha; α-diaryl Prolinol silicon ether carries out Diels-Alder reaction as catalyzer; in 20 ~ 120 hours reaction times, add DBU at 25 DEG C, series connection Diels-Alder/Aldol reacts 2 hours; at 0 DEG C, MsCl, TEA dehydration reaction obtains target product in 15 minutes.
3. method according to claim 2, is characterized in that: described chiral alpha, and the general structure of α-diaryl Prolinol silicon ether catalyst is:
wherein: R
1, R
2be selected from H, CH arbitrarily
3, tBu, OCH
3, R
3be selected from TMS, TES, TBS arbitrarily, R
4be selected from H arbitrarily, OTBS.
4. method according to claim 2, is characterized in that: described acid additives is selected from protonic acid arbitrarily; Described DBU is 1,8-diazabicylo [5.4.0] 11 carbon-7-alkene; Described MsCl is methane sulfonyl chloride; Described TEA is triethylamine.
5. method according to claim 2, is characterized in that: described 3-ethanoyl coumarin compound, two olefine aldehydrs, chiral alpha, and the mol ratio of α-diaryl Prolinol silicon ether, acid additives, DBU, MsCl, TEA is 1:2:0.2:0.2:0.5:2:5.
6. method according to claim 2, is characterized in that: described organic solvent is polar solvent or non-polar solvent, and described polar solvent is toluene, methylene dichloride, chloroform, acetonitrile, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF), ethyl acetate; Non-polar solvent is benzene, sherwood oil.
7. coumarin skeleton polynuclear compound according to claim 1 is for the preparation of the purposes in Hepatoma therapy medicine.
8. coumarin skeleton polynuclear compound according to claim 1 is for the preparation of the purposes in treatment kidney medicine.
9. coumarin skeleton polynuclear compound according to claim 1 is for the preparation of the purposes in treatment cervical cancer medicine.
10. coumarin skeleton polynuclear compound according to claim 1 is for the preparation of the purposes in treatment prostate cancer medicine.
11. coumarin skeleton polynuclear compounds according to claim 1 for the preparation for the treatment of lymphoid tumor medicament in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374912.0A CN103408530B (en) | 2013-08-26 | 2013-08-26 | Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310374912.0A CN103408530B (en) | 2013-08-26 | 2013-08-26 | Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103408530A CN103408530A (en) | 2013-11-27 |
| CN103408530B true CN103408530B (en) | 2015-05-27 |
Family
ID=49601587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310374912.0A Expired - Fee Related CN103408530B (en) | 2013-08-26 | 2013-08-26 | Coumarin skeleton polycyclic compound with biological activity as well as preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103408530B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089634A (en) * | 1984-08-20 | 1992-02-18 | Georgia Tech Research Corporation | Isocoumarins with cationic substituents |
| US5324648A (en) * | 1987-04-28 | 1994-06-28 | Georgia Tech Research Corporation | Substituted isocoumarins as serine protease inhibitors and anti-inflammatory agents |
| US5554611A (en) * | 1993-11-08 | 1996-09-10 | Cassella Aktiengesellschaft | Use of coumarin derivatives |
| WO2002008217A2 (en) * | 2000-07-21 | 2002-01-31 | Chugai Seiyaku Kabushiki Kaisha | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| WO2002092076A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| CN1506359A (en) * | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | Coumarin amide derivative and its prepn, medicinal composition and use |
| WO2009036656A1 (en) * | 2007-09-18 | 2009-03-26 | Nanjing Zhongrui Medicine Co., Ltd | Coumarin derivatives, preparation processes and uses thereof |
| CN101613388A (en) * | 2009-07-16 | 2009-12-30 | 中国科学院大连化学物理研究所 | The coumarin kind compound of glucuronidation and application thereof |
| WO2012070024A1 (en) * | 2010-11-28 | 2012-05-31 | Metasignal Therapeutics Inc. | Carbonic anhydrase inhibitors with antimetastatic activity |
| CN102532084A (en) * | 2010-12-29 | 2012-07-04 | 华北制药集团新药研究开发有限责任公司 | Coumarin compound and preparation method and application thereof |
| CN102964326A (en) * | 2012-11-06 | 2013-03-13 | 北京大学 | Compound with MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as preparation method and application of compound |
-
2013
- 2013-08-26 CN CN201310374912.0A patent/CN103408530B/en not_active Expired - Fee Related
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089634A (en) * | 1984-08-20 | 1992-02-18 | Georgia Tech Research Corporation | Isocoumarins with cationic substituents |
| US5324648A (en) * | 1987-04-28 | 1994-06-28 | Georgia Tech Research Corporation | Substituted isocoumarins as serine protease inhibitors and anti-inflammatory agents |
| US5554611A (en) * | 1993-11-08 | 1996-09-10 | Cassella Aktiengesellschaft | Use of coumarin derivatives |
| WO2002008217A2 (en) * | 2000-07-21 | 2002-01-31 | Chugai Seiyaku Kabushiki Kaisha | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| WO2002092076A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| CN1506359A (en) * | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | Coumarin amide derivative and its prepn, medicinal composition and use |
| WO2009036656A1 (en) * | 2007-09-18 | 2009-03-26 | Nanjing Zhongrui Medicine Co., Ltd | Coumarin derivatives, preparation processes and uses thereof |
| CN101613388A (en) * | 2009-07-16 | 2009-12-30 | 中国科学院大连化学物理研究所 | The coumarin kind compound of glucuronidation and application thereof |
| WO2012070024A1 (en) * | 2010-11-28 | 2012-05-31 | Metasignal Therapeutics Inc. | Carbonic anhydrase inhibitors with antimetastatic activity |
| CN102532084A (en) * | 2010-12-29 | 2012-07-04 | 华北制药集团新药研究开发有限责任公司 | Coumarin compound and preparation method and application thereof |
| CN102964326A (en) * | 2012-11-06 | 2013-03-13 | 北京大学 | Compound with MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as preparation method and application of compound |
Non-Patent Citations (3)
| Title |
|---|
| Aminocatalytic asymmetric inverse-electron-demandaza-Diels–Alder reaction of N-Ts-1-aza-1,3-butadienes based on coumarin cores;Jun-Long Li et al;《Chem Commun》;20100211;第46卷(第15期);第2665-2667页 * |
| 含香豆素骨架的缩氨基硫脲化合物的合成和抑菌活性研究;徐翠莲 等;《化学通报》;20090918;第1卷(第9期);第815-819页 * |
| 香豆素衍生物合成研究进展;董社英 等;《化学世界》;20090825;第1卷(第8期);第494-497页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103408530A (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brahmachari | Room temperature one-pot green synthesis of coumarin-3-carboxylic acids in water: a practical method for the large-scale synthesis | |
| Mao et al. | Phosphine-catalyzed [4+ 2] annulation of allenoate with sulfamate-derived cyclic imines: A reaction mode involving γ′-carbon of α-substituted allenoate | |
| Han et al. | FeCl3-catalyzed stereoselective construction of spirooxindole tetrahydroquinolines via tandem 1, 5-hydride transfer/ring closure | |
| Zhao et al. | Flueggines A and B, two new dimeric indolizidine alkaloids from Flueggea virosa | |
| Yu et al. | Phosphine-catalyzed [3+ 2] cycloaddition of sulfamate-derived cyclic imines with allenoate: Synthesis of sulfamate-fused dihydropyrroles | |
| Zareai et al. | Synthesis of functionalized furo [3, 2-c] coumarins via a one-pot oxidative pseudo three-component reaction in poly (ethylene glycol) | |
| Liao et al. | Hypersubones A and B, new polycyclic acylphloroglucinols with intriguing adamantane type cores from Hypericum subsessile | |
| Mugishima et al. | Absolute stereochemistry of citrinadins A and B from marine-derived fungus | |
| Liu et al. | Isatisine A, a novel alkaloid with an unprecedented skeleton from leaves of Isatis indigotica | |
| Zhao et al. | Virosaines A and B, two new birdcage-shaped Securinega alkaloids with an unprecedented skeleton from Flueggea virosa | |
| Ma et al. | Chemical library and structure–activity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents | |
| Brahmachari et al. | Visible light-induced and singlet oxygen-mediated photochemical conversion of 4-hydroxy-α-benzopyrones to 2-hydroxy-3-oxo-2, 3-dihydrobenzofuran-2-carboxamides/carboxylates using rose bengal as a photosensitizer | |
| Guranova et al. | Rh (II)-catalyzed spirocyclization of α-diazo homophthalimides with cyclic ethers | |
| Boonsompat et al. | An IMDAF cycloaddition approach toward the synthesis of the lycopodium alkaloid (±)-fawcettidine | |
| Zi et al. | Multicomponent cascade reaction by metal-free aerobic oxidation for synthesis of highly functionalized 2-amino-4-coumarinyl-5-arylpyrroles | |
| Pettit et al. | Antineoplastic agents. 585. Isolation of Bridelia ferruginea anticancer podophyllotoxins and synthesis of 4-aza-podophyllotoxin structural modifications1 | |
| Li et al. | Transition metal-free cascade reactions of alkynols to afford isoquinolin-1 (2 H)-one and dihydroisobenzofuran derivatives | |
| Ghandi et al. | Synthesis of cyclopentadiene-fused chromanones via one-pot multicomponent reactions | |
| Ding et al. | Construction of Eight-Membered Cyclic Diaryl Sulfides via Domino Reaction of Arynes with Thioaurone Analogues and DFT Study on the Reaction Mechanism | |
| Vinoth et al. | Palladium-Catalyzed Internal Nucleophile-Assisted Hydration–Olefin Insertion Cascade: Diastereoselective Synthesis of 2, 3-Dihydro-1 H-inden-1-ones | |
| Tanpure et al. | Gold (I)-catalyzed highly diastereo-and enantioselective constructions of bicyclo [3.2. 1] oct-6-ene frameworks via (4+ 3)-cycloadditions | |
| Markad et al. | Biomimetic collective total synthesis of bioactive carbazole alkaloids indizoline, mafaicheenamine A, claulamine A, claulansine A, and the proposed claulamine E | |
| Politanskaya et al. | p-Toluenesulfonic acid mediated one-pot cascade synthesis and cytotoxicity evaluation of polyfluorinated 2-aryl-2, 3-dihydroquinolin-4-ones and their derivatives | |
| Zhou et al. | Divergent Domino Reactions of Prop-2-ynylsulfonium Salts: Access to Sulfur-Containing Benzo-Fused Dioxabicyclo [3.3. 1] nonanes and Dihydrofuro [2, 3-c] chromenes | |
| Noland et al. | Fe-Catalyzed Domino Intramolecular Nucleophilic Substitution of 4-Hydroxychromen-2-one and Pyran-2-one/Ring Opening of Activated Arene: An Easy Access to 2, 3-Disubstituted Furo [3, 2,-c] coumarins and Furo [3, 2,-c] pyran-4-ones via Nonsymmetric Triarylmethanes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150527 |